keyword
MENU ▼
Read by QxMD icon Read
search

Primary mediastinal lymphoma

keyword
https://www.readbyqxmd.com/read/29771253/axicabtagene-ciloleucel-for-the-treatment-of-relapsed-refractory-b-cell-non-hodgkin-s-lymphomas
#1
P Sharma, G T King, S S Shinde, E Purev, A Jimeno
B-cell non-Hodgkin's lymphomas are the most common hematological malignancies, which despite improvements in chemo-immunotherapy, carry a uniformly poor prognosis in the relapsed/refractory setting. CD19 is an antigen expressed on the surface of most malignancies arising from the B cells, and adoptive transfer of anti-CD19 chimeric antigen receptor (CAR)-expressing T cells has been shown to be effective in treating these B-cell malignancies. Axicabtagene ciloleucel (axi-cel, KTE-C19) is an autologous anti-CD19 CAR T-cell therapy which has shown high overall response rates and a manageable safety profile in patients with relapsed or refractory B-cell malignancies who lack effective and curative treatment options...
March 2018: Drugs of Today
https://www.readbyqxmd.com/read/29756323/primary-mediastinal-histiocytic-sarcoma-presenting-as-pleural-effusion
#2
Jie-Yang Jhuang, Wei-Yu Chen, Shih-Sung Chuang
Histiocytic sarcoma (HS) is a rare malignant neoplasm showing morphological and immunophenotypic features of mature tissue histiocytes. As HS may mimic non-Hodgkin lymphoma (NHL) pathologically, before the era of immunohistochemistry, many previously reported cases were misdiagnosed NHL. Up to date, there are only a few reports delineating the cytological features in fine-needle aspiration or bronchoalveolar lavage, but not in the effusion fluid yet. Herein, we report the case of a 61-year-old male with a mediastinal tumor presenting with malignant pleural effusion...
May 13, 2018: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/29748435/end-of-treatment-and-serial-pet-imaging-in-primary-mediastinal-b-cell-lymphoma-following-dose-adjusted-epoch-r-a-paradigm-shift-in-clinical-decision-making
#3
Christopher Melani, Ranjana Advani, Mark Roschewski, Kelsey M Walters, Clara C Chen, Lucia Baratto, Mark A Ahlman, Milos D Miljkovic, Seth M Steinberg, Jessica Lam, Margaret Shovlin, Kieron Dunleavy, Stefania Pittaluga, Elaine S Jaffe, Wyndham H Wilson
Dose-adjusted-EPOCH-R obviates the need for radiotherapy in most patients with primary mediastinal B-cell lymphoma. End-of-treatment PET, however, does not accurately identify patients at risk of treatment failure, thereby confounding clinical decision making. To define the role of PET in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R, we extended enrollment and follow-up on our published phase II trial and independent series. Ninety-three patients received dose-adjusted-EPOCH-R without radiotherapy...
May 10, 2018: Haematologica
https://www.readbyqxmd.com/read/29741502/advances-in-the-management-of-primary-mediastinal-large-b-cell-lymphoma
#4
Ranjana H Advani
No abstract text is available yet for this article.
January 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29741220/nhl-in-adolescents-and-young-adults-a-unique-population
#5
REVIEW
Jessica Hochberg, Allyson Flower, Laurence Brugieres, Mitchell S Cairo
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid malignancies with high incidence in adolescents and young adults (AYAs). The most common diseases include diffuse large B-cell lymphoma, anaplastic large cell lymphoma, Burkitt lymphoma, lymphoblastic lymphoma, and primary mediastinal large B-cell lymphoma. In comparison to younger children and adults, AYAs (15-39 years) with NHL present a specific set of challenges including variations in tumor biology, inconsistent treatment, pharmacodynamics, and psychosocial barriers...
May 9, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29720487/metabolic-heterogeneity-on-baseline-18fdg-pet-ct-scan-is-a-predictor-of-outcome-in-primary-mediastinal-b-cell-lymphoma
#6
Luca Ceriani, Lisa Milan, Maurizio Martelli, Andrés J M Ferreri, Luciano Cascione, Pier Luigi Zinzani, Alice Di Rocco, Annarita Conconi, Anastasios Stathis, Franco Cavalli, Monica Bellei, Kelly Cozens, Elena Porro, Luca Giovanella, Peter W Johnson, Emanuele Zucca
An important unmet need in the management of primary mediastinal B-cell lymphoma (PMBCL) is to identify the patients for whom first line therapy will fail, in order to intervene before the lymphoma becomes refractory. High heterogeneity of intratumoral 18F-fluorodeoxyglucose (18FDG) uptake distribution on positron emission tomography/computed tomography (PET/CT) scans has been suggested as a possible marker of chemo-resistance in solid tumors. In the present study, we investigated the prognostic value of metabolic heterogeneity (MH) in 103 PMBCL patients prospectively enrolled in the International Extranodal Lymphoma Study Group (IELSG) 26 study, aimed at clarifying the role of PET in this lymphoma subtype...
May 2, 2018: Blood
https://www.readbyqxmd.com/read/29709235/-tunisian-national-protocol-for-adult-hodgkin-s-lymphoma-treatment-results-of-a-therapeutic-regimen-adapted-to-the-2-cycle-ct-response-about-444-patients
#7
Raihane Ben Lakhal, Sondos Hdiji, Sami Zriba, Amina Mokrani, Mohamed Adnen Laatiri, Yossra BenYoussef, Faten Ezzaier, Nabil Toumi, Salwa Ladeb, Hanen BenSalah, Sameh Tebra, Hatem Frikha, Taha Messai, Jamel Daoued, Noureddine Bouaouina, Monji Maalej, Mounir Frikha, Tarek BenOthmen, Slim BenAhmed, Abderrahim Khelif, Fehmi Msaddek, Amel Mezlini, Moez Elloumi, Balkis Meddeb
OBJECTIVE: In Tunisia, the management of Adult Hodgkin's Lymphoma (HL) has been standardized since 1999. We propose in this study to report the therapeutic results of the national protocol of adult HL treatment (MDH2008). PATIENTS AND METHODS: Our study is prospective multicenter interesting 444 patients followed for HL between July 2008 and June 2013 and treated according to the MDH2008 protocol. The median age of our patients was 30 years. B symptoms were present in 62...
April 27, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29686956/management-of-primary-mediastinal-b-cell-lymphoma-in-pregnancy
#8
Sidra Khalid, Aariez Khalid, Hamed Daw, Praful Maroo
Primary mediastinal B-cell lymphoma (PMBCL) is a subtype of non-Hodgkin's lymphoma, which occurs rarely in pregnancy. We present a case of a pregnant 22-year-old female who presented with syncope and dyspnea. Computed tomography (CT) chest showed an anterior mediastinal mass, and its biopsy showed PMBCL. Since she was in her second trimester, we decided to treat her with rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Our case emphasizes the safety of chemotherapy in the second and third trimesters, with good maternal and fetal outcomes...
February 21, 2018: Curēus
https://www.readbyqxmd.com/read/29675060/utility-and-safety-of-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-in-patients-with-mediastinal-and-hilar-lymphadenopathy-western-region-experience
#9
Ahmed A Aljohaney
AIMS: The aim of the study was to evaluate the clinical utility and safety of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients with mediastinal and hilar lymphadenopathy and to explicitly describe the utility of this procedure in patient's outcome. METHODS: A retrospective review and analysis was conducted on 52 patients with mediastinal or hilar lymphadenopathy who underwent EBUS-TBNA from June 2012 to June 2016. All the patients were evaluated by computed tomography (CT) chest with contrast before EBUS examination...
April 2018: Annals of Thoracic Medicine
https://www.readbyqxmd.com/read/29672465/lactate-dehydrogenase-levels-and-18f-fdg-pet-ct-metrics-differentiate-between-mediastinal-hodgkin-s-lymphoma-and-primary-mediastinal-b-cell-lymphoma
#10
Rayan H M Alkhawtani, Walter Noordzij, Andor W J M Glaudemans, Rozemarijn S van Rijn, Hilde T van der Galiën, Hans Balink, Marcel Nijland, Hugo J A Adams, Gerwin Huls, Tom van Meerten, Thomas C Kwee
PURPOSE: This study aims to investigate whether clinical, laboratory, and fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT findings can discriminate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma (PMBCL). PATIENTS AND METHODS: This retrospective study included 56 patients (42 with mediastinal Hodgkin's lymphoma and 14 with PBMCL). Differences in clinical, laboratory, and F-FDG PET/CT metrics were assessed between Hodgkin's lymphoma and PMBCL...
April 18, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29665940/-advances-in-the-molecular-diagnosis-and-therapy-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-review
#11
Yi Wang, Bing Xia, Yi-Zhuo Zhang
Diffuse large B-cell lymphoma (DLBCL) is biologically aggressive and most common pathological type of non-Hodgkin's lymphoma (NHL), and about one-third of these patients are refractory or relapsed ultimately. Based on the molecular heterogeneity, DLBCL can be divided into 3 main molecular subtypes: germinal center B-cell like (GCB), activated B-cell like (ABC) and primary mediastinal B-cell lymphoma (PMBL). Arising from B cells at distinct stages of differentiation, these subtypes are also diverse in mechanisms of oncogenic activation...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29660176/the-role-of-radiotherapy-as-salvage-and-or-consolidation-treatment-in-relapsed-refractory-and-high-risk-diffuse-large-b-cell-lymphoma
#12
Eric Grignano, Jérémy Laurent, Bénédicte Deau, Barbara Burroni, Didier Bouscary, Youlia M Kirova
OBJECTIVE: Many salvage therapies have been proposed for relapsed/refractory (R/R) diffuse large B-cell lymphomas or for consolidation in the case of suboptimal response. Radiotherapy (RT) is one modality of salvage therapy, but its place is currently not well defined. METHOD: This paper reports a retrospective review of patients receiving unplanned radiotherapy for R/R diffuse large B-cell lymphoma (DLBCL) or primary mediastinal B-cell lymphoma (PMBCL), or as consolidation therapy after second line chemotherapy, treated in our hospital...
April 16, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29655961/chimeric-antigen-receptor-t-cell-therapy-for-non-hodgkin-lymphoma
#13
REVIEW
Armin Ghobadi
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy. More than 20,000 people in United States, more than 37,000 people in Europe and more than 199,000 people worldwide die of NHL every year. Recent advances in immunotherapeutic approaches for cancer have resulted in development of new classes of very effective immunotherapeutic approaches including chimeric antigen receptor T (CAR-T) cell therapy that are designed to bypass cancer immune evasion. Here, we review recent advances in CAR-T cell therapy for NHL...
April 11, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29564225/mechanisms-of-immune-evasion-and-immune-modulation-by-lymphoma-cells
#14
REVIEW
Thomas Menter, Alexandar Tzankov
Purpose: Targeting cancer cells by modulating the immune system has become an important new therapeutic option in many different malignancies. Inhibition of CTLA4/B7 and PD1/PDL1 signaling is now also being investigated and already successfully applied to various hematologic malignancies. Methods: A literature review of PubMed and results of our own studies were compiled in order to give a comprehensive overview on this topic. Results: We elucidate the pathophysiological role of immunosuppressive networks in lymphomas, ranging from changes in the cellular microenvironment composition to distinct signaling pathways such as PD1/PDL1 or CTLA4/B7/CD28...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29515770/ruxolitinib-significantly-enhances-in-vitro-apoptosis-in-hodgkin-lymphoma-and-primary-mediastinal-b-cell-lymphoma-and-survival-in-a-lymphoma-xenograft-murine-model
#15
Sanghoon Lee, Tishi Shah, Changhong Yin, Jessica Hochberg, Janet Ayello, Erin Morris, Carmella van de Ven, Mitchell S Cairo
Hodgkin lymphoma (HL) and primary mediastinal B-cell lymphoma (PMBL) share similar molecular features by gene expression profiling. Frequent gains of chromosome 9p exhibit higher Janus Kinase 2 (JAK2) transcript levels with increased JAK2 activity, suggesting aberrant activity of JAK2 and STAT pathways. This signaling pathway alteration may in part play an important role in the pathogenesis and/or chemoradiotherapy resistance in HL and PMBL. Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) including those harboring the JAK2V617F mutation...
February 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29501729/stat6-is-a-cargo-of-exportin-1-biological-relevance-in-primary-mediastinal-b-cell-lymphoma
#16
Hadjer Miloudi, Karen Leroy, Fabrice Jardin, Brigitte Sola
Primary mediastinal B-cell lymphoma (PMBL) is a distinct B-cell lymphoma subtype with unique clinicopathological and molecular features. PMBL cells are characterised by several genetic abnormalities that conduct to the constitutive activation of the Janus kinase 2/signal transducer and activator of transcription 6 (JAK2/STAT6) signalling pathway. Among recurrent genetic changes in PMBL, we previously reported that the XPO1 gene encoding exportin 1 that controls the nuclear export of cargo proteins and RNAs, is mutated (p...
June 2018: Cellular Signalling
https://www.readbyqxmd.com/read/29467182/somatic-il4r-mutations-in-primary-mediastinal-large-b-cell-lymphoma-lead-to-constitutive-jak-stat-signaling-activation
#17
Elena Viganò, Jay Gunawardana, Anja Mottok, Tessa Van Tol, Katina Mak, Fong Chun Chan, Lauren Chong, Elizabeth Chavez, Bruce Woolcock, Katsuyoshi Takata, David Twa, Hennady P Shulha, Adèle Telenius, Olga Kutovaya, Stacy S Hung, Shannon Healy, Susana Ben-Neriah, Karen Leroy, Philippe Gaulard, Arjan Diepstra, Robert Kridel, Kerry J Savage, Lisa Rimsza, Randy Gascoyne, Christian Steidl
Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct subtype of diffuse large B-cell lymphoma thought to arise from thymic medullary B cells. Gene mutations underlying the molecular pathogenesis of the disease are incompletely characterized. Here, we describe novel somatic IL4R mutations in 15 of 62 primary cases of PMBCL (24.2%) and in all PMBCL-derived cell lines tested. The majority of mutations (11/21; 52%) were hotspot single nucleotide variants in exon 8, leading to an I242N amino acid change in the transmembrane domain...
May 3, 2018: Blood
https://www.readbyqxmd.com/read/29463854/autologous-stem-cell-transplantation-for-primary-mediastinal-b-cell-lymphoma-long-term-outcome-and-role-of-post-transplant-radiotherapy-a-report-of-the-european-society-for-blood-and-marrow-transplantation
#18
Irit Avivi, Ariane Boumendil, Hervé Finel, Arnon Nagler, Aïda Botelho de Sousa, Josep Maria Ribera Santasusana, Elizabeth Vandenberghe, Boris Afanasyev, Dominique Bordessoule, José Maria Moraleda, Eulogio Conde Garcia, David Pohlreich, Gonzalo Gutiérrez Garcia, Kirsty Thomson, Reuven Or, Dietrich Beelen, Eliana Zuffa, Sebastian Giebel, Christian Berthou, Gilles Salles, Angela Melpignano, Silvia Montoto, Peter Dreger
The purpose of this retrospective registry study was to investigate the outcome of autoSCT for primary mediastinal B-cell lymphoma (PMBCL) in the rituximab era, including the effects of eventual post-transplant radiotherapy (RT) consolidation. Patients with PMBCL aged between 18 and 70 years who were treated with a first autoSCT between 2000 and 2012 and registered with the EBMT were eligible. Eighty-six patients with confirmed PMBCL and the full data set required for this analysis were evaluable. Sixteen patients underwent autoSCT in remission after first-line therapy (CR/PR1), 44 patients were transplanted with chemosensitive relapsed or primary refractory disease (CR/PR >1), and 24 patients were chemorefractory at the time of autoSCT...
February 20, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29449733/dedifferentiated-primary-mediastinal-liposarcoma-mimicking-a-thymic-tumor
#19
A Mansuet-Lupo, F Lococo, F Larousserie, M Alifano, R Saliceti
Mediastinal tumors are heterogeneous and the diagnosis depends on their location in the mediastinum. The most frequent tumors are germinal tumor, lymphoma and thymoma. The clinical and radiological aspects are often not sufficient to orient the diagnosis and biopsy is necessary to confirmed it. Here, we present a rare case of an anterior mediastinal mass incidentally detected in a 63 years old man during assessment for asthma. The lesion was presumptively diagnosed as a thymic epithelial tumor based on location and radiological characteristics...
December 2017: Pathologica
https://www.readbyqxmd.com/read/29397833/-c-myc-gene-and-protein-expression-in-paraffin-wax-of-t-lymphoblastic-lymphoma-and-leukemia-patients-and-its-effect-on-the-prognosis
#20
Xiao-Dong Zhang, Li-Ming He, Lei Ma, Zhang-Guo Chang
OBJECTIVE: To explore the relevance between the expression of C-MYC gene and protein of patients with T lymphoblastic lymphoma and leukemia(T-LBL/ALL) and its effect on the prognosis. METHODS: Paraffin specimens from 60 cases of T-LBL/ALL with detailed follow-up during May 2005 to May 2016 were selected as study group; at same time 20 cases of reactive hyperplasia (RH) of lymphonuedes were selected as control group. The immunohistochemical EnVision method was used to mark the terminal deoxynucleotidyl transferase (TDT), myeloperoxidase (MPO), Ki-67 and C-MYC immune tissue...
February 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
keyword
keyword
57043
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"